- Home
- QTTB vs DCGO Comparison
QTTB vs DCGO Comparison
Compare QTTB & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- DCGO
- Stock Information
- Founded
- QTTB 2015
- DCGO 2015
- Country
- QTTB United States
- DCGO United States
- Employees
- QTTB N/A
- DCGO N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- DCGO Managed Health Care
- Sector
- QTTB Health Care
- DCGO Health Care
- Exchange
- QTTB Nasdaq
- DCGO Nasdaq
- Market Cap
- QTTB 434.0M
- DCGO 435.6M
- IPO Year
- QTTB N/A
- DCGO N/A
- Fundamental
- Price
- QTTB $3.31
- DCGO $4.22
- Analyst Decision
- QTTB Buy
- DCGO Strong Buy
- Analyst Count
- QTTB 8
- DCGO 5
- Target Price
- QTTB $29.14
- DCGO $6.10
- AVG Volume (30 Days)
- QTTB 690.6K
- DCGO 722.0K
- Earning Date
- QTTB 11-07-2024
- DCGO 11-07-2024
- Dividend Yield
- QTTB N/A
- DCGO N/A
- EPS Growth
- QTTB N/A
- DCGO 300.38
- EPS
- QTTB N/A
- DCGO 0.29
- Revenue
- QTTB N/A
- DCGO $694,968,328.00
- Revenue This Year
- QTTB N/A
- DCGO $2.14
- Revenue Next Year
- QTTB N/A
- DCGO N/A
- P/E Ratio
- QTTB N/A
- DCGO $14.79
- Revenue Growth
- QTTB N/A
- DCGO 30.19
- 52 Week Low
- QTTB $3.02
- DCGO $2.75
- 52 Week High
- QTTB $53.79
- DCGO $5.70
- Technical
- Relative Strength Index (RSI)
- QTTB 16.87
- DCGO 51.16
- Support Level
- QTTB $3.02
- DCGO $4.08
- Resistance Level
- QTTB $3.77
- DCGO $4.65
- Average True Range (ATR)
- QTTB 1.69
- DCGO 0.26
- MACD
- QTTB -0.34
- DCGO -0.02
- Stochastic Oscillator
- QTTB 1.16
- DCGO 32.54
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.